Yosef Refaeli

This inventor holds 6 USPTO granted patents. Top assignees: University of Pennsylvania, The Wistar Institute. Active years: 1997-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yosef Refaeli. Retrieved from https://idiyas.com/inventor/yosef-refaeli-644h7i02

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Boston, MA (US) (1997 - 2003)
Philadelphia, PA (US) (2005)

Company Filing History:

6 out of 2,659

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 1997-2005

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6838236 - VPR function and activity (2005-01-04),

2. 6667157 - Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus VPR protein (2003-12-23),

3. 5780238 - VPR receptor protein (1998-07-14),

4. 5780220 - Methods and compositions for inhibiting HIV replication (1998-07-14),

5. 5763190 - Methods for the identification of compounds capable of inducing the (1998-06-09),

6. 5639598 - Method and kit for identification of antiviral agents capable of (1997-06-17),

Title: The Innovative Contributions of Yosef Refaeli

Introduction

Yosef Refaeli is a prominent inventor based in Boston, MA, known for his significant contributions to the field of pharmaceutical sciences. With a total of 6 patents, he has made remarkable strides in developing treatments for diseases characterized by hyperproliferating undifferentiated cells, such as cancer.

Latest Patents

Among his latest patents, Refaeli has developed pharmaceutical compositions that comprise the HIV protein VPR or nucleic acid molecules encoding VPR. These compositions are aimed at treating patients suffering from diseases characterized by hyperproliferating undifferentiated cells. Additionally, he has disclosed methods for identifying compounds with anti-HIV activity, particularly those that modulate the activity of VPR or inhibit its binding to the HIV protein Gag. Another notable patent involves methods of inhibiting cellular proliferation using VPR protein or nucleotide sequences that encode VPR. This includes methods for preventing lymphocyte activation and treating individuals diagnosed with autoimmune diseases, proliferating cell diseases, and graft versus host disease.

Career Highlights

Refaeli has worked with esteemed institutions such as the University of Pennsylvania and The Wistar Institute. His work has been pivotal in advancing the understanding and treatment of various diseases through innovative pharmaceutical compositions.

Collaborations

Throughout his career, Refaeli has collaborated with notable individuals in the field, including David B. Weiner and David Nathan Levy. These collaborations have further enhanced his research and contributions to the scientific community.

Conclusion

Yosef Refaeli's innovative work in the field of pharmaceuticals has led to significant advancements in treating serious diseases. His patents and collaborations reflect his commitment to improving healthcare through scientific innovation.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]